Deepa Jagadeesh
Overview
Explore the profile of Deepa Jagadeesh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, et al.
Bone Marrow Transplant
. 2023 Nov;
59(2):211-216.
PMID: 37973893
Outcomes are poor for patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) post chimeric antigen receptor T-cell (CAR-T) therapy. Two CD19-directed therapies, tafasitamab- cxix plus lenalidomide (tafa-len) and...
12.
Desai S, Spinner M, Evens A, Sykorova A, Bachanova V, Goyal G, et al.
Blood Adv
. 2023 Sep;
7(23):7295-7303.
PMID: 37729621
In the pre-novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3...
13.
Aleixo G, Wei W, Chen P, Gandhi N, Anwer F, Dean R, et al.
Bone Marrow Transplant
. 2023 Sep;
58(12):1384-1389.
PMID: 37699993
Recently there has been a growing interest in evaluating body composition as a marker for prognosis in cancer patients. The association of body composition parameters and outcomes has not been...
14.
Parameswaran N, Luo L, Zhang L, Chen J, DiFilippo F, Androjna C, et al.
Leukemia
. 2023 Aug;
37(10):2050-2057.
PMID: 37573404
T cell lymphomas (TCL) are heterogeneous, aggressive, and have few available targeted therapeutics. In this study, we determined that CD6, an established T cell marker, was expressed at high levels...
15.
Brooks T, Jagadeesh D
Leuk Lymphoma
. 2023 Jul;
64(7):1223-1224.
PMID: 37501586
No abstract available.
16.
Iyer S, Huen A, Ai W, Jagadeesh D, Lechowicz M, Okada C, et al.
Haematologica
. 2023 Jul;
109(1):209-219.
PMID: 37439343
Tenalisib, a selective phosphoinositide-3-kinase δ/γ, and salt-inducible-kinase-3 inhibitor has shown efficacy and was well-tolerated in patients with T-cell lymphoma (TCL). In vitro studies suggest a synergistic anti-tumor potential for the...
17.
Mato A, Woyach J, Brown J, Ghia P, Patel K, Eyre T, et al.
N Engl J Med
. 2023 Jul;
389(1):33-44.
PMID: 37407001
Background: Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options...
18.
Hamilton B, Rybicki L, Li H, Lucas T, Corrigan D, Kalaycio M, et al.
Blood Adv
. 2023 Jun;
7(16):4505-4513.
PMID: 37352262
Tacrolimus (Tac)/methotrexate (MTX) is standard graft-versus-host disease (GVHD) prophylaxis; however, is associated with several toxicities. Tac, reduced-dose MTX (mini-MTX), and mycophenolate mofetil (MMF) have been used but never compared with...
19.
Mishra R, Dima D, Kumar S, Mian A, Taneja A, Karna R, et al.
Hematol Oncol
. 2023 Jun;
41(5):884-893.
PMID: 37309225
With improvement in survival after chronic lymphocytic leukemia (CLL) diagnosis, the real-world burden of second hematological malignancies (SHM) has not been comprehensively assessed in recent era. We analyzed risk, incidence,...
20.
Awada H, Hajj Ali A, Ali M, Sauter C, Hamilton B, Kalaycio M, et al.
Eur J Haematol
. 2023 Mar;
110(6):780-783.
PMID: 36949569
No abstract available.